The global Type 1 Diabetes (T1D) market size is predicted to grow from US$ 2175 million in 2025 to US$ 2877 million in 2031; it is expected to grow at a CAGR of 4.8% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Type 1 diabetes (T1D) is an autoimmune disease that occurs when a persons pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the bodys immune system. The cause of this attack is still being researched, however scientists believe the cause may have genetic and environmental components.

According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents wealth and the improvement of health awareness will drive the demand for medicines.

Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.

Infinity Market Research newest research report, the Type 1 Diabetes (T1D) Industry Forecast looks at past sales and reviews total world Type 1 Diabetes (T1D) sales in 2024, providing a comprehensive analysis by region and market sector of projected Type 1 Diabetes (T1D) sales for 2025 through 2031. With Type 1 Diabetes (T1D) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Type 1 Diabetes (T1D) industry.

This Insight Report provides a comprehensive analysis of the global Type 1 Diabetes (T1D) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Type 1 Diabetes (T1D) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Type 1 Diabetes (T1D) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Type 1 Diabetes (T1D) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Type 1 Diabetes (T1D).

This report presents a comprehensive overview, market shares, and growth opportunities of Type 1 Diabetes (T1D) market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Rapid Acting Insulin Analogs
    Long Acting Insulin Analogs
    Premix Insulin Analogs

Segmentation by Application:

    Children
    Adults

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Novo Nordisk
    Sanofi
    Eli Lilly
    Merck
    Boehringer Ingelheim
    Samsung Bioepis
    Biocon
    Astellas
    Janssen
    Bristol-Myers Squibb
    Lexicon
    Sanofi

Key Questions Addressed in this Report

What is the 10-year outlook for the global Type 1 Diabetes (T1D) market?
What factors are driving Type 1 Diabetes (T1D) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Type 1 Diabetes (T1D) market opportunities vary by end market size?
How does Type 1 Diabetes (T1D) break out by Type, by Application?